A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease
Satish Keshav(John Radcliffe Hospital), Ole Haagen Nielsen(University of Copenhagen), S Howaldt, Séverine Vermeire(KU Leuven), I Rácz(Petz Aladár Megyei Oktató Kórház), Pirow Bekker(ChemoCentryx (United States)), Tomáš Vaňásek, Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Thomas J. Schall(ChemoCentryx (United States)), Yaron Niv(Rabin Medical Center), Per Karlén(Karolinska Institutet), David J. Hetzel(Royal Adelaide Hospital), Walter Reinisch(Medical University of Vienna), Mauro Bafutto, Robert Petryka
Cited by 134
Related Papers
Identification of a major co-receptor for primary isolates of HIV-1
|Nature|1996|3.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A new class of membrane-bound chemokine with a CX3C motif
|Nature|1997|2k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k